Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 121,900 shares, a growth of 12.6% from the September 30th total of 108,300 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 279,800 shares, the days-to-cover ratio is presently 0.4 days.
Coeptis Therapeutics Price Performance
Shares of COEP stock traded down $0.01 during trading hours on Thursday, hitting $0.20. The stock had a trading volume of 158,724 shares, compared to its average volume of 319,749. Coeptis Therapeutics has a one year low of $0.15 and a one year high of $1.33. The stock’s 50-day moving average price is $0.19 and its two-hundred day moving average price is $0.26. The stock has a market capitalization of $7.94 million, a price-to-earnings ratio of -0.44 and a beta of -0.91.
Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) last released its quarterly earnings results on Friday, August 16th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. As a group, equities research analysts predict that Coeptis Therapeutics will post -0.26 earnings per share for the current fiscal year.
Coeptis Therapeutics Company Profile
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
Read More
- Five stocks we like better than Coeptis Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Following Congress Stock Trades
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- The How and Why of Investing in Gold Stocks
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
